Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
Phosphodiesterase 4B (PDE4B) has been evaluated as a genetic risk factor for schizophrenia. Selective PDE4 inhibitor drugs have antipsychotic-like effects and reduce tardive dyskinesia-like movements in animal models. We investigated whether PDE4B genetic variants are associated with antipsychotic-induced tardive dyskinesia incidence and severity in schizophrenia patients. Our sample consisted of 169 Caucasian patients taking typical antipsychotic medication for at least 1 year. We found two PDE4B gene variants to be nominally associated with tardive dyskinesia (rs1338719 and rs7528545) in the overall population and two other variants nominally associated with the presence of tardive dyskinesia and severity in female patients (rs1890196 and rs783036). None of these results survived correction for multiple testing. Overall, our results do not support a genetic association between tardive dyskinesia and PDE4B.
Souza
Renan P
RP
Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Remington
Gary
G
Meltzer
Herbert Y
HY
Lieberman
Jeffrey A
JA
Kennedy
James L
JL
Wong
Albert H C
AH
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000235:genetics*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D012737:Sex Factors; D055815:Young Adult
D014150:Antipsychotic Agents; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4